Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The SPACE-T study is a clinical trial for people with advanced small-cell lung cancer (SCLC) whose cancer has returned or spread despite previous treatment and whose general health is reduced (ECOG performance status 2). The study will include 57 participants at about 15 sites in Germany. The study is testing tarlatamab, a treatment that helps the immune system recognize and attack cancer cells. Participants will receive tarlatamab through a vein, starting with a lower dose of 1 mg, followed by doses of 10 mg. Treatment will then generally be given every two weeks. The main purpose of the study is to find out how effective tarlatamab is in this group of patients by assessing how many participants are alive 12 months after starting the study. The study will also examine how well the treatment controls the cancer, including cancer that has spread to the brain, how well participants tolerate the treatment, its side effects, and its impact on quality of life. Patients with poorer general health are often not included in clinical trials, even though they represent an important part of the people treated for SCLC in everyday clinical practice. The SPACE-T study aims to provide more information about whether tarlatamab is effective and feasible for these patients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony przez biopsję rak płuc drobnokomórkowy
- •Rak wrócił lub rozprzestrzeniał się pomimo poprzedniego leczenia
- •Wcześniej otrzymano co najmniej jedno leczenie przeciwrakowe
- •Wcześniej otrzymano leczenie chemią, lekami na immunoterapię i innymi standardowymi lekami
- •Mierzalne zmiany nowotworowe widoczne w badaniach obrazowych
- •Ogólny stan zdrowia umiarkowanie obniżony
- •Pisemna zgoda na udział w badaniu
✗ Disqualifies
- •Bardzo dobry lub bardzo zły stan ogólny (ECOG 0, 1, 3 lub 4)
- •Spodziewana długość życia poniżej 3 miesięcy
- •Przerzuty do mózgu z nasilającymi się objawami neurологicznych w ostatnich 3 tygodniach
- •Niedozwolenie szpiku kostnego (zbyt niskie liczby komórek krwi)
- •Zaawansowana choroba wątroby z nieprawidłowymi wynikami badań
- •Zaawansowana choroba nerek (zbyt niska funkcja nerek)
- •Słabość mięśnia sercowego
- •Istotne nagromadzenie płynu wokół serca
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 4, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (8)
Evangelische Lungenklinik Berlin
Berlin, Germany
Universitätsklinikum Carl Gustav Carus
Dresden, Germany
Universitätsklinikum Essen
Essen, Germany
Malteser Krankenhaus St. Franziskus-Hospital
Flensburg, Germany
Universitätsklinikum Frankfurt
Frankfurt, Germany
Johannes Wesling Klinikum Minden
Minden, Germany
Klinikum der Universität München
München, Germany
Klinikum Stuttgart
Stuttgart, Germany
Trial contact
Marcel Wiesweg, MD
Tim Overkamp, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/5/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.